Search

Displaying results 1221 - 1230 of 10000 in total
  1. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. … [A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831]

  2. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. … The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents.

  3. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. … It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization.

    Categories: N-substituted Glycines
  4. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … [L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies.

  5. Drug

    Gluconic Acid

    go.drugbank.com/drugs/DB13180
    ApprovedInvestigational

    Commonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.

    Mixtures: Isolyte S in Dextrose, Plasmalyte 148 In 5% Dextrose Inj
  6. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    [A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … [A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed

    Synonyms: N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valineMixtures: CARDIK - IN® 160/2.5, CARDIK - IN® 160/2.5
  7. Drug

    Phosphoric acid

    go.drugbank.com/drugs/DB09394
    ApprovedInvestigational

    Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

    Mixtures: PERİFERAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ, 500 ML SETLİ, PERİFERAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ, 1000 ML SETLİCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. … The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.

  9. Drug

    Procaine benzylpenicillin

    go.drugbank.com/drugs/DB09320
    ApprovedVet approved

    This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. … It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts.

    Mixtures: SENCAIN-S 100.000 IU/300.000 IU IM ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 FLAKON + 1 AMPUL, PROKAIN PENICILLIN 3.1.400.000 IU IM ENJEKSİYONLUK TOZ, 10 ADET
  10. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

    Mixtures: Menjugate 10 Mikrogramm Injektionssuspension in einer Fertigspritze, Mencevax Ac Pws Inj 2500mcg/vial